Financial Performance - The company reported a basic earnings per share of 2.03 yuan for 2024, an increase of 48.18% compared to 1.37 yuan in 2023 [1] - The net profit for 2024 reached 8.28 billion yuan, reflecting a growth of 49.19% from 5.55 billion yuan in 2023 [1] - The operating revenue for 2024 was 28.17 billion yuan, up 34.14% from 21 billion yuan in 2023 [1] - The return on equity (ROE) improved to 37.69% in 2024, compared to 33.98% in 2023, marking a 10.92% increase [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 30,216.8 million shares, accounting for 74.28% of the circulating shares, with a change of 1,814.2 million shares from the previous period [1] - The largest shareholder, Yang Ying, holds 13,807.73 million shares, representing 33.94% of the total share capital [2] - The second-largest shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., holds 6,520.01 million shares, which is 16.03% of the total [2] Dividend Distribution - The company announced a dividend distribution plan of 10 shares for every 6.2 shares held (including tax) [3]
特宝生物:2024年报净利润8.28亿 同比增长49.19%